Companies Dominating the Somatostatin Analogs Landscape
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries Ltd
- Midatech Pharma PLC
- Ipsen Pharma, Chiasma Inc.
- Peptron, Inc
- CRINETICS PHARMACEUTICALS
- Dauntless Pharmaceuticals
- Camurus AB
- Pfizer Inc.
Browse Key Market Insights with Data Illustration:
In the News
- Novartis AG announced that it has received a favorable opinion for Pluvicto a radioligand therapy, in combination with androgen deprivation therapy (ADT) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). Furthermore, the positive opinion is based on data from the Phase III VISION study, which would significantly improve overall survival in PSMA-positive mCRPC patients and provide transformative innovation to more patients around the world.
- Sun Pharmaceutical Industries Ltd. teamed up with Philogen SpA for the commercialization of Nidlegy, a brand-new immunotherapy drug that Philogen is creating to treat both melanoma and non-melanoma skin cancers in New Zealand, Australia, and Europe.
